Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 May 19;8(4):470-484.
doi: 10.1080/21505594.2017.1292196. Epub 2017 Feb 8.

Therapeutic options for carbapenem-resistant Enterobacteriaceae infections

Enrico Maria Trecarichi  1 , Mario Tumbarello  1
Affiliations
Review

Therapeutic options for carbapenem-resistant Enterobacteriaceae infections

Enrico Maria Trecarichi et al. Virulence. .

Abstract

In recent years, carbapenem resistance among Enterobacteriaceae has dramatically increased and represents an important threat to global health. The optimal therapeutic management of carbapenem-resistant Enterobacteriaceae (CRE) infections has not been established, because to date, no clinical trials have been performed with this objective. We aimed to summarize in the present review data provided by previous observational clinical studies that have investigated the impact of different treatment strategies on the outcome of CRE infections. Most of these studies reported that combination therapy with 2 or more drugs is superior to monotherapy in providing a survival benefit. The use of carbapenems in association with other active drugs is likely ineffective for CRE isolates with carbapenem Minimum Inhibitory Concentrations (MICs) >8 mg/l. The effectiveness of further therapeutic options for the treatment of extensively or pan-drug-resistant Enterobacteriaceae infections has been reported in vivo and in vitro, although few cases/case series have been reported. Novel antimicrobials that are effective against CRE are urgently needed.

Keywords: carbapenem-resistant Enterobacteriaceae; combination therapy; double-carbapenem combination; monotherapy; mortality.

PubMed Disclaimer

References

    1. van Duin D, Doi Y. The global epidemiology of carbapenemase-producing Enterobacteriaceae. Virulence 2016; 11:1-10; https://doi.org/10.1080/21505594.2016.1222343 - DOI - PMC - PubMed
    1. Viale P, Giannella M, Lewis R, Trecarichi EM, Petrosillo N, Tumbarello M. Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections. Expert Rev Anti Infect Ther 2013; 11(10):1053-63; PMID:24073806; https://doi.org/10.1586/14787210.2013.836057 - DOI - PubMed
    1. Tängdén T, Giske CG. Global dissemination of extensively drug-resistant carbapenemase-producing Enterobacteriaceae: clinical perspectives on detection, treatment and infection control. J Intern Med 2015; 277(5):501-12; PMID:25556628; https://doi.org/10.1111/joim.12342 - DOI - PubMed
    1. Tzouvelekis LS, Markogiannakis A, Psichogiou M, Tassios PT, Daikos GL. Carbapenemases in Klebsiella pneumoniae and other Enterobacteriaceae: an evolving crisis of global dimensions. Clin Microbiol Rev 2012; 25(4):682-707; PMID:23034326; https://doi.org/10.1128/CMR.05035-11 - DOI - PMC - PubMed
    1. Cantón R, Akóva M, Carmeli Y, Giske CG, Glupczynski Y, Gniadkowski M, Livermore DM, Miriagou V, Naas T, Rossolini GM, et al.. Rapid evolution and spread of carbapenemases among Enterobacteriaceae in Europe. Clin Microbiol Infect 2012; 18(5):413-31; PMID:22507109; https://doi.org/10.1111/j.1469-0691.2012.03821.x - DOI - PubMed

MeSH terms

Substances

LinkOut - more resources